Alexion Pharmaceuticals, Inc. (ALXN): Price and Financial Metrics
ALXN Stock Summary
- With a market capitalization of $33,758,711,002, Alexion Pharmaceuticals Inc has a greater market value than 92.71% of US stocks.
- ALXN's current price/earnings ratio is 55.95, which is higher than 80.13% of US stocks with positive earnings.
- Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 15.62% of US stocks have a lower such ratio.
- If you're looking for stocks that are quantitatively similar to Alexion Pharmaceuticals Inc, a group of peers worth examining would be JAZZ, HPE, EXPE, FSLR, and COHR.
- Visit ALXN's SEC page to see the company's official filings. To visit the company's web site, go to www.alexion.com.
ALXN Stock Price Chart Interactive Chart >
ALXN Price/Volume Stats
| Current price | $153.65 | 52-week high | $162.60 |
| Prev. close | $154.49 | 52-week low | $72.67 |
| Day low | $152.95 | Volume | 2,372,300 |
| Day high | $155.48 | Avg. volume | 2,844,386 |
| 50-day MA | $156.18 | Dividend yield | N/A |
| 200-day MA | $123.97 | Market Cap | 33.78B |
Alexion Pharmaceuticals, Inc. (ALXN) Company Bio
Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.
ALXN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $153.65 | $403.08 | 162% |
We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 72th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 163.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Alexion Pharmaceuticals Inc, consider:
- The company has produced more trailing twelve month cash flow than 87.77% of its sector Healthcare.
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately only 22.82% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Alexion Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 157% |
| 1% | 160% |
| 2% | 162% |
| 3% | 165% |
| 4% | 167% |
| 5% | 170% |
ANTM, CVS, CSTL, HCSG, and CAH can be thought of as valuation peers to ALXN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Latest ALXN News From Around the Web
Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.
BioCryst Short-Sellers Lose ControlThe Company BioCryst (NASDAQ:BCRX) develops novel, oral and small molecules that inhibit enzymes playing a key role in biological pathways of rare diseases. Biocryst has built a world-class sales team to launch Orladeyo in the US and EU. Biocryst has signed a licensing agreement with Torii to launch the product... |
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion PharmaceuticalsSAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - MDCA, VIE, CLGX, ALXN, TCFHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Top Merger Stocks Held By Fund Managers, Mid-Q1 2021Stock prices have risen more in the past 11 months than anyone could have anticipated. And as you might expect, many companies have been using their inflated stocks to buy other companies. In fact, only two of the top ten deals I have complied from the 13F filings are pure... |
ALXN Price Returns
| 1-mo | -1.31% |
| 3-mo | 24.08% |
| 6-mo | 43.61% |
| 1-year | 66.85% |
| 3-year | 29.84% |
| 5-year | 9.62% |
| YTD | -1.66% |
| 2020 | 44.47% |
| 2019 | 11.08% |
| 2018 | -18.59% |
| 2017 | -2.26% |
| 2016 | -35.86% |
Continue Researching ALXN
Want to see what other sources are saying about Alexion Pharmaceuticals Inc's financials and stock price? Try the links below:Alexion Pharmaceuticals Inc (ALXN) Stock Price | Nasdaq
Alexion Pharmaceuticals Inc (ALXN) Stock Quote, History and News - Yahoo Finance
Alexion Pharmaceuticals Inc (ALXN) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...